{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:06:18Z","timestamp":1791396378333,"version":"4.3.3"},"reference-count":156,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T00:00:00Z","timestamp":1672099200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81700453"],"award-info":[{"award-number":["81700453"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Asian Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.ajps.2022.100771","type":"journal-article","created":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T02:19:07Z","timestamp":1672280347000},"page":"100771","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Oncolytic virus-based hepatocellular carcinoma treatment: Current status, intravenous delivery strategies, and emerging combination therapeutic solutions"],"prefix":"10.1016","volume":"18","author":[{"given":"Xinguo","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaonan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ajps.2022.100771_bib0001","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"10.1016\/j.ajps.2022.100771_bib0002","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jhep.2019.11.006","article-title":"Milestones in the pathogenesis and management of primary liver cancer","volume":"72","author":"Nault","year":"2020","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.ajps.2022.100771_bib0003","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrurol.2018.10","article-title":"Potentiating prostate cancer immunotherapy with oncolytic viruses","volume":"15","author":"Lee","year":"2018","journal-title":"Nat Rev Urol"},{"issue":"3","key":"10.1016\/j.ajps.2022.100771_bib0004","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01643-19","article-title":"Experimental evolution generates novel oncolytic vesicular stomatitis viruses with improved replication in virus-resistant pancreatic cancer cells","volume":"94","author":"Seegers","year":"2020","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.ajps.2022.100771_bib0005","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/mt.2009.231","article-title":"Engineered Newcastle disease virus as an improved oncolytic agent against hepatocellular carcinoma","volume":"18","author":"Altomonte","year":"2010","journal-title":"Mol Ther"},{"issue":"3","key":"10.1016\/j.ajps.2022.100771_bib0006","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1128\/JVI.02040-09","article-title":"van den Pol AN. Some attenuated variants of vesicular stomatitis virus show enhanced oncolytic activity against human glioblastoma cells relative to normal brain cells","volume":"84","author":"Wollmann","year":"2010","journal-title":"J Virol"},{"issue":"5","key":"10.1016\/j.ajps.2022.100771_bib0007","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1007\/s12274-021-4031-6","article-title":"Emerging systemic delivery strategies of oncolytic viruses: a key step toward cancer immunotherapy","volume":"15","author":"Ban","year":"2022","journal-title":"Nano Res"},{"issue":"8","key":"10.1016\/j.ajps.2022.100771_bib0008","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1158\/1535-7163.MCT-20-0863","article-title":"Oncolytic vaccinia virus gene modification and cytokine expression effects on tumor infection, immune response, and killing","volume":"20","author":"Inoue","year":"2021","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"10.1016\/j.ajps.2022.100771_bib0009","doi-asserted-by":"crossref","first-page":"5908","DOI":"10.1038\/s41467-021-26003-6","article-title":"An oncolytic virus expressing a full-length antibody enhances antitumor innate immune response to glioblastoma","volume":"12","author":"Xu","year":"2021","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.ajps.2022.100771_bib0010","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.3390\/v13071200","article-title":"The effect of herpes simplex virus-type-1 (HSV-1) oncolytic immunotherapy on the tumor microenvironment","volume":"13","author":"Uche","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.ajps.2022.100771_bib0011","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.omto.2021.05.002","article-title":"Current strategies in engaging oncolytic viruses with antitumor immunity","volume":"22","author":"Boagni","year":"2021","journal-title":"Mol Ther Oncolytics"},{"issue":"52","key":"10.1016\/j.ajps.2022.100771_bib0012","doi-asserted-by":"crossref","first-page":"7720","DOI":"10.1038\/sj.onc.1209041","article-title":"Unshackling the links between reovirus oncolysis, Ras signaling, translational control and cancer","volume":"24","author":"Shmulevitz","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.ajps.2022.100771_bib0013","first-page":"1","article-title":"Emerging systemic delivery strategies of oncolytic viruses: a key step toward cancer immunotherapy","author":"Ban","year":"2022","journal-title":"Nano Res"},{"issue":"8","key":"10.1016\/j.ajps.2022.100771_bib0014","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41577-018-0014-6","article-title":"Integrating oncolytic viruses in combination cancer immunotherapy","volume":"18","author":"Bommareddy","year":"2018","journal-title":"Nat Rev Immunol"},{"issue":"20","key":"10.1016\/j.ajps.2022.100771_bib0015","doi-asserted-by":"crossref","first-page":"7505","DOI":"10.3390\/ijms21207505","article-title":"Clinical application of oncolytic viruses: a systematic review","volume":"21","author":"Cook","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ajps.2022.100771_bib0016","doi-asserted-by":"crossref","first-page":"866","DOI":"10.3389\/fimmu.2018.00866","article-title":"Oncolytic viral therapy and the immune system: a double-edged sword against cancer","volume":"9","author":"Marelli","year":"2018","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.ajps.2022.100771_bib0017","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1021\/acs.nanolett.9b00145","article-title":"Genetically engineered cell membrane nanovesicles for oncolytic adenovirus delivery: a versatile platform for cancer virotherapy","volume":"19","author":"Lv","year":"2019","journal-title":"Nano Lett"},{"issue":"Pt 7","key":"10.1016\/j.ajps.2022.100771_bib0018","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1099\/vir.0.000098","article-title":"Progress in clinical oncolytic virus-based therapy for hepatocellular carcinoma","volume":"96","author":"Jebar","year":"2015","journal-title":"J Gen Virol"},{"key":"10.1016\/j.ajps.2022.100771_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2022.101530","article-title":"Current landscape and perspective of oncolytic viruses and their combination therapies","volume":"25","author":"Su","year":"2022","journal-title":"Transl Oncol"},{"issue":"6","key":"10.1016\/j.ajps.2022.100771_bib0020","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.ajps.2022.100771_bib0021","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/14656566.2017.1419185","article-title":"Advances in the treatment of HIV\/HCV coinfection in adults","volume":"19","author":"Schlabe","year":"2018","journal-title":"Expert Opin Pharmacother"},{"issue":"10003","key":"10.1016\/j.ajps.2022.100771_bib0022","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/S0140-6736(15)61412-X","article-title":"Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013","volume":"386","author":"Schweitzer","year":"2015","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.ajps.2022.100771_bib0023","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.7314\/APJCP.2012.13.8.3741","article-title":"Bicluster and pathway enrichment analysis of HCV-induced cirrhosis and hepatocellular carcinoma","volume":"13","author":"Cheng","year":"2012","journal-title":"Asian Pac J Cancer Prev"},{"issue":"5","key":"10.1016\/j.ajps.2022.100771_bib0024","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/hep.28785","article-title":"The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.ajps.2022.100771_bib0025","doi-asserted-by":"crossref","first-page":"621","DOI":"10.3390\/cancers14030621","article-title":"Hepatocellular carcinoma: molecular pathogenesis and therapeutic advances","volume":"14","author":"Cucarull","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ajps.2022.100771_bib0026","doi-asserted-by":"crossref","first-page":"16018","DOI":"10.1038\/nrdp.2016.18","article-title":"Hepatocellular carcinoma","volume":"2","author":"Llovet","year":"2016","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"10.1016\/j.ajps.2022.100771_bib0027","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3390\/genes8040123","article-title":"C-MYC-making liver sick: role of c-MYC in hepatic cell function, homeostasis and disease","volume":"8","author":"Zheng","year":"2017","journal-title":"Genes"},{"issue":"2","key":"10.1016\/j.ajps.2022.100771_bib0028","doi-asserted-by":"crossref","first-page":"68","DOI":"10.4161\/org.4.2.5851","article-title":"Wnt signal transduction pathways","volume":"4","author":"Komiya","year":"2008","journal-title":"Organogenesis"},{"issue":"1","key":"10.1016\/j.ajps.2022.100771_bib0029","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S1016-8478(23)17384-5","article-title":"Mutation hotspots in the \u03b2-catenin gene: lessons from the human cancer genome databases","volume":"42","author":"Kim","year":"2019","journal-title":"Mol Cells"},{"key":"10.1016\/j.ajps.2022.100771_bib0030","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1016\/j.biopha.2018.03.005","article-title":"MiR-300 regulates the epithelial-mesenchymal transition and invasion of hepatocellular carcinoma by targeting the FAK\/PI3K\/AKT signaling pathway","volume":"103","author":"Wang","year":"2018","journal-title":"Biomed Pharmacother"},{"issue":"10127","key":"10.1016\/j.ajps.2022.100771_bib0031","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","volume":"391","author":"Forner","year":"2018","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ajps.2022.100771_bib0032","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/apt.14913","article-title":"Review article: systemic treatment of hepatocellular carcinoma","volume":"48","author":"Pinter","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ajps.2022.100771_bib0033","first-page":"108","article-title":"The survival rate of hepatocellular carcinoma in Asian countries: a systematic review and meta-analysis","volume":"19","author":"Hassanipour","year":"2020","journal-title":"EXCLI J"},{"issue":"15","key":"10.1016\/j.ajps.2022.100771_bib0034","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1056\/NEJMra1713263","article-title":"Hepatocellular Carcinoma","volume":"380","author":"Villanueva","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajps.2022.100771_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2019.101946","article-title":"Current strategies for the treatment of intermediate and advanced hepatocellular carcinoma","volume":"82","author":"Vogel","year":"2020","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"10.1016\/j.ajps.2022.100771_bib0036","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1111\/liv.14817","article-title":"Lenvatinib versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: an inverse probability of treatment weighting analysis","volume":"41","author":"Casadei-Gardini","year":"2021","journal-title":"Liver Int"},{"issue":"7","key":"10.1016\/j.ajps.2022.100771_bib0037","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1111\/hepr.13505","article-title":"Comparative analysis of liver functional reserve during lenvatinib and sorafenib for advanced hepatocellular carcinoma","volume":"50","author":"Terashima","year":"2020","journal-title":"Hepatol Res"},{"issue":"2","key":"10.1016\/j.ajps.2022.100771_bib0038","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.jhep.2019.09.025","article-title":"Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma","volume":"72","author":"Cheng","year":"2020","journal-title":"J Hepatol"},{"issue":"10","key":"10.1016\/j.ajps.2022.100771_bib0039","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.3390\/cancers12103025","article-title":"Immune checkpoint inhibitors in hepatocellular carcinoma: current status and novel perspectives","volume":"12","author":"Federico","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.ajps.2022.100771_bib0040","article-title":"Immune checkpoint inhibitors in the treatment of HCC","volume":"10","author":"Donisi","year":"2020","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.ajps.2022.100771_bib0041","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1186\/s13046-019-1396-4","article-title":"From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma","volume":"38","author":"Fu","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.ajps.2022.100771_bib0042","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.3390\/cancers12102859","article-title":"Immunotherapy for hepatocellular carcinoma: a 2021 update","volume":"12","author":"Kole","year":"2020","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.ajps.2022.100771_bib0043","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1673129","article-title":"The promise of adoptive cellular immunotherapies in hepatocellular carcinoma","volume":"9","author":"Hendrickson","year":"2020","journal-title":"Oncoimmunology"},{"issue":"9232","key":"10.1016\/j.ajps.2022.100771_bib0044","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/S0140-6736(00)02654-4","article-title":"Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial","volume":"356","author":"Takayama","year":"2000","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ajps.2022.100771_bib0045","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41587-021-00929-0","article-title":"First CAR-T therapy to target BCMA gets FDA nod","volume":"39","year":"2021","journal-title":"Nat Biotechnol"},{"issue":"11","key":"10.1016\/j.ajps.2022.100771_bib0046","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1158\/1078-0432.CCR-19-1835","article-title":"Enhancing chimeric antigen receptor T-cell efficacy in solid tumors","volume":"26","author":"Fuca","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ajps.2022.100771_bib0047","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1158\/1078-0432.CCR-16-1203","article-title":"Targeting alpha-fetoprotein (AFP)-MHC complex with CAR T-cell therapy for liver cancer","volume":"23","author":"Liu","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajps.2022.100771_bib0048","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.655697","article-title":"Hepatocellular carcinoma immune landscape and the potential of immunotherapies","volume":"12","author":"Giraud","year":"2021","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.ajps.2022.100771_bib0049","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.ymthe.2020.01.003","article-title":"Immune modulation by telomerase-specific oncolytic adenovirus synergistically enhances antitumor efficacy with anti-PD1 antibody","volume":"28","author":"Kanaya","year":"2020","journal-title":"Mol Ther"},{"key":"10.1016\/j.ajps.2022.100771_bib0050","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.omto.2018.10.005","article-title":"Abscopal effect in non-injected tumors achieved with cytokine-armed oncolytic adenovirus","volume":"11","author":"Havunen","year":"2018","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.ajps.2022.100771_bib0051","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3389\/fonc.2017.00202","article-title":"Oncolytic viruses-natural and genetically engineered cancer immunotherapies","volume":"7","author":"Jhawar","year":"2017","journal-title":"Front Oncol"},{"issue":"9","key":"10.1016\/j.ajps.2022.100771_bib0052","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/s41573-019-0029-0","article-title":"Optimizing oncolytic virotherapy in cancer treatment","volume":"18","author":"Harrington","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.ajps.2022.100771_bib0053","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12985-022-01779-1","article-title":"Oncolytic therapy with vaccinia virus carrying IL-24 for hepatocellular carcinoma","volume":"19","author":"Deng","year":"2022","journal-title":"Virol J"},{"issue":"2","key":"10.1016\/j.ajps.2022.100771_bib0054","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1089\/hum.2017.212","article-title":"Fighting cancer with viruses: oncolytic virus therapy in china","volume":"29","author":"Wei","year":"2018","journal-title":"Hum Gene Ther"},{"issue":"10","key":"10.1016\/j.ajps.2022.100771_bib0055","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1111\/cas.13027","article-title":"Oncolytic virus therapy: a new era of cancer treatment at dawn","volume":"107","author":"Fukuhara","year":"2016","journal-title":"Cancer Sci"},{"issue":"8","key":"10.1016\/j.ajps.2022.100771_bib0056","doi-asserted-by":"crossref","first-page":"705","DOI":"10.2217\/imt-2019-0033","article-title":"Talimogene laherparepvec: review of its mechanism of action and clinical efficacy and safety","volume":"11","author":"Raman","year":"2019","journal-title":"Immunotherapy"},{"issue":"3","key":"10.1016\/j.ajps.2022.100771_bib0057","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/cas.13492","article-title":"Third-generation oncolytic herpes simplex virus inhibits the growth of liver tumors in mice","volume":"109","author":"Nakatake","year":"2018","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ajps.2022.100771_bib0058","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2147\/TCRM.S128575","article-title":"Antitumor effects of oncolytic herpes simplex virus type 2 against colorectal cancer in vitro and in vivo","volume":"13","author":"Yin","year":"2017","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.ajps.2022.100771_bib0059","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3389\/fonc.2017.00195","article-title":"Oncolytic viruses-interaction of virus and tumor cells in the battle to eliminate cancer","volume":"7","author":"Howells","year":"2017","journal-title":"Front Oncol"},{"key":"10.1016\/j.ajps.2022.100771_bib0060","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.omto.2019.09.004","article-title":"Intravenous injections of a rationally selected oncolytic herpes virus as a potent virotherapy for hepatocellular carcinoma","volume":"15","author":"Luo","year":"2019","journal-title":"Mol Ther Oncolytics"},{"issue":"1","key":"10.1016\/j.ajps.2022.100771_bib0061","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/bjc.2012.569","article-title":"Hyaluronan, fluid pressure, and stromal resistance in pancreas cancer","volume":"108","author":"Provenzano","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ajps.2022.100771_bib0062","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.omto.2021.01.015","article-title":"Efficient antitumor effects of a novel oncolytic adenovirus fully composed of species B adenovirus serotype 35","volume":"20","author":"Ono","year":"2021","journal-title":"Mol Ther Oncolytics"},{"issue":"5286","key":"10.1016\/j.ajps.2022.100771_bib0063","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1126\/science.274.5286.373","article-title":"An adenovirus mutant that replicates selectively in p53-deficient human tumor cells","volume":"274","author":"Bischoff","year":"1996","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.ajps.2022.100771_bib0064","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.3390\/cancers14112798","article-title":"Emerging therapies for hepatocellular carcinoma (HCC)","volume":"14","author":"Chakraborty","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ajps.2022.100771_bib0065","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1471-2407-12-17","article-title":"Golgi protein 73 versus alpha-fetoprotein as a biomarker for hepatocellular carcinoma: a diagnostic meta-analysis","volume":"12","author":"Zhou","year":"2012","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.ajps.2022.100771_bib0066","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1478-3231.2011.02666.x","article-title":"Sphingosine kinase 1 promotes tumour cell migration and invasion via the S1P\/EDG1 axis in hepatocellular carcinoma","volume":"32","author":"Bao","year":"2012","journal-title":"Liver Int"},{"issue":"12","key":"10.1016\/j.ajps.2022.100771_bib0067","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1631\/jzus.B1900089","article-title":"A novel oncolytic adenovirus inhibits hepatocellular carcinoma growth","volume":"20","author":"Bai","year":"2019","journal-title":"J Zhejiang Univ Sci B"},{"issue":"11","key":"10.1016\/j.ajps.2022.100771_bib0068","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1016\/j.ymthe.2019.07.019","article-title":"Recombinant adenovirus expressing a soluble fusion protein PD-1\/CD137L subverts the suppression of CD8(+) T cells in HCC","volume":"27","author":"Zhang","year":"2019","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.ajps.2022.100771_bib0069","first-page":"300","article-title":"Genetically engineered recombinant adenovirus expressing interleukin2 for hepatocellular carcinoma therapy","volume":"17","author":"Sun","year":"2018","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.ajps.2022.100771_bib0070","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3389\/fonc.2017.00096","article-title":"Genetically engineered vaccinia viruses as agents for cancer treatment, imaging, and transgene delivery","volume":"7","author":"Haddad","year":"2017","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.ajps.2022.100771_bib0071","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S1470-2045(08)70107-4","article-title":"Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial","volume":"9","author":"Park","year":"2008","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ajps.2022.100771_bib0072","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nm.3089","article-title":"Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer","volume":"19","author":"Heo","year":"2013","journal-title":"Nat Med"},{"issue":"185","key":"10.1016\/j.ajps.2022.100771_bib0073","doi-asserted-by":"crossref","first-page":"185ra63","DOI":"10.1126\/scitranslmed.3005361","article-title":"Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans","volume":"5","author":"Kim","year":"2013","journal-title":"Sci Transl Med"},{"issue":"3","key":"10.1016\/j.ajps.2022.100771_bib0074","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/mt.2014.243","article-title":"Phase 1 study of intratumoral Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus, in pediatric cancer patients","volume":"23","author":"Cripe","year":"2015","journal-title":"Mol Ther"},{"issue":"2","key":"10.1016\/j.ajps.2022.100771_bib0075","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.surg.2015.03.044","article-title":"Oncolytic gene therapy with recombinant vaccinia strain GLV-2b372 efficiently kills hepatocellular carcinoma","volume":"158","author":"Ady","year":"2015","journal-title":"Surgery"},{"issue":"42","key":"10.1016\/j.ajps.2022.100771_bib0076","doi-asserted-by":"crossref","first-page":"71489","DOI":"10.18632\/oncotarget.17288","article-title":"Evolutionary cancer-favoring engineered vaccinia virus for metastatic hepatocellular carcinoma","volume":"8","author":"Yoo","year":"2017","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.ajps.2022.100771_bib0077","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1158\/2326-6066.CIR-21-0171","article-title":"Neoadjuvant intravenous oncolytic vaccinia virus therapy promotes anticancer immunity in patients","volume":"10","author":"Samson","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ajps.2022.100771_bib0078","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.canlet.2019.12.029","article-title":"Tackling hepatocellular carcinoma with individual or combinatorial immunotherapy approaches","volume":"473","author":"Tagliamonte","year":"2020","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ajps.2022.100771_bib0079","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/978-1-4939-2727-2_19","article-title":"A phase 2, open-label, randomized study of Pexa-Vec (JX-594) administered by intratumoral injection in patients with unresectable primary hepatocellular carcinoma","volume":"1317","author":"Breitbach","year":"2015","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.ajps.2022.100771_bib0080","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.semcancer.2019.07.013","article-title":"Recent insights into apoptosis and toxic autophagy: the roles of MDA-7\/IL-24, a multidimensional anti-cancer therapeutic","volume":"66","author":"Emdad","year":"2020","journal-title":"Semin Cancer Biol"},{"issue":"13","key":"10.1016\/j.ajps.2022.100771_bib0081","first-page":"3605","article-title":"Oncolytic vesicular stomatitis virus for treatment of orthotopic hepatocellular carcinoma in immune-competent rats","volume":"63","author":"Ebert","year":"2003","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.ajps.2022.100771_bib0082","doi-asserted-by":"crossref","first-page":"3265","DOI":"10.1158\/0008-5472.CAN-03-3753","article-title":"Syncytia induction enhances the oncolytic potential of vesicular stomatitis virus in virotherapy for cancer","volume":"64","author":"Ebert","year":"2004","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.ajps.2022.100771_bib0083","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1089\/hum.2007.163","article-title":"rVSV(M Delta 51)-M3 is an effective and safe oncolytic virus for cancer therapy","volume":"19","author":"Wu","year":"2008","journal-title":"Hum Gene Ther"},{"issue":"3","key":"10.1016\/j.ajps.2022.100771_bib0084","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.bbrc.2016.05.005","article-title":"Hepatitis C virus core protein enhances hepatocellular carcinoma cells to be susceptible to oncolytic vesicular stomatitis virus through down-regulation of HDAC4","volume":"474","author":"Moon","year":"2016","journal-title":"Biochem Biophys Res Commun"},{"issue":"9","key":"10.1016\/j.ajps.2022.100771_bib0085","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1007\/s00705-019-04306-w","article-title":"Changes to virus taxonomy and the International Code of Virus Classification and Nomenclature ratified by the International Committee on Taxonomy of Viruses","volume":"164","author":"Walker","year":"2019","journal-title":"Arch Virol 2019"},{"key":"10.1016\/j.ajps.2022.100771_bib0086","first-page":"69","article-title":"Reovirus in cancer therapy: an evidence-based review","volume":"3","author":"Clements","year":"2014","journal-title":"Oncolytic Virother"},{"key":"10.1016\/j.ajps.2022.100771_bib0087","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1476-4598-10-20","article-title":"Pro-inflammatory cytokine\/chemokine production by reovirus treated melanoma cells is PKR\/NF-kappaB mediated and supports innate and adaptive anti-tumour immune priming","volume":"10","author":"Steele","year":"2011","journal-title":"Mol Cancer"},{"issue":"3","key":"10.1016\/j.ajps.2022.100771_bib0088","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1136\/gutjnl-2016-312009","article-title":"Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer","volume":"67","author":"Samson","year":"2018","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.ajps.2022.100771_bib0089","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1089\/hum.2018.095","article-title":"Oncolytic activity of a novel influenza A virus carrying granulocyte-macrophage colony-stimulating factor in hepatocellular carcinoma","volume":"30","author":"Penghui","year":"2019","journal-title":"Hum Gene Ther"},{"issue":"6","key":"10.1016\/j.ajps.2022.100771_bib0090","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1002\/cbin.11559","article-title":"A recombinant influenza virus with a CTLA4-specific scFv inhibits tumor growth in a mouse model","volume":"45","author":"Lei","year":"2021","journal-title":"Cell Biol Int"},{"issue":"3","key":"10.1016\/j.ajps.2022.100771_bib0091","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3390\/biomedicines7030066","article-title":"Breaking therapy resistance: an update on oncolytic Newcastle disease virus for improvements of cancer therapy","volume":"7","author":"Schirrmacher","year":"2019","journal-title":"Biomedicines"},{"issue":"3","key":"10.1016\/j.ajps.2022.100771_bib0092","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01677-19","article-title":"Engineering Newcastle disease virus as an oncolytic vector for intratumoral delivery of immune checkpoint inhibitors and immunocytokines","volume":"94","author":"Vijayakumar","year":"2020","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.ajps.2022.100771_bib0093","doi-asserted-by":"crossref","first-page":"179","DOI":"10.14218\/JCTH.2021.00553","article-title":"Newcastle disease virus\/HK84: next potential star for targeted immunotherapy of hepatocellular carcinoma?","volume":"10","author":"Huang","year":"2022","journal-title":"J Clin Transl Hepatol"},{"issue":"2","key":"10.1016\/j.ajps.2022.100771_bib0094","doi-asserted-by":"crossref","first-page":"284","DOI":"10.14218\/JCTH.2021.00284","article-title":"Oncolytic activity of wild-type Newcastle disease virus HK84 against hepatocellular carcinoma associated with activation of type I interferon signaling","volume":"10","author":"Chen","year":"2022","journal-title":"J Clin Transl Hepatol"},{"issue":"30","key":"10.1016\/j.ajps.2022.100771_bib0095","doi-asserted-by":"crossref","first-page":"48443","DOI":"10.18632\/oncotarget.10305","article-title":"A classical PKA inhibitor increases the oncolytic effect of M1 virus via activation of exchange protein directly activated by cAMP 1","volume":"7","author":"Li","year":"2016","journal-title":"Oncotarget"},{"issue":"42","key":"10.1016\/j.ajps.2022.100771_bib0096","doi-asserted-by":"crossref","first-page":"E4504","DOI":"10.1073\/pnas.1408759111","article-title":"Identification and characterization of alphavirus M1 as a selective oncolytic virus targeting ZAP-defective human cancers","volume":"111","author":"Lin","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"10.1016\/j.ajps.2022.100771_bib0097","doi-asserted-by":"crossref","first-page":"5055","DOI":"10.1021\/acs.nanolett.2c00699","article-title":"Boarding oncolytic viruses onto tumor-homing bacterium-vessels for augmented cancer immunotherapy","volume":"22","author":"Sun","year":"2022","journal-title":"Nano Lett"},{"issue":"4","key":"10.1016\/j.ajps.2022.100771_bib0098","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1172\/JCI122287","article-title":"Oncolytic viruses: overcoming translational challenges","volume":"129","author":"Martinez-Quintanilla","year":"2019","journal-title":"J Clin Invest"},{"issue":"12","key":"10.1016\/j.ajps.2022.100771_bib0099","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.3390\/pharmaceutics13122192","article-title":"Giving oncolytic viruses a free ride: carrier cells for oncolytic virotherapy","volume":"13","author":"Reale","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ajps.2022.100771_bib0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.172991","article-title":"Mesenchymal stem cells as carriers for systemic delivery of oncolytic viruses","volume":"874","author":"Hadrys","year":"2020","journal-title":"Eur J Pharmacol"},{"issue":"6","key":"10.1016\/j.ajps.2022.100771_bib0101","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1158\/1078-0432.CCR-20-1499","article-title":"Mesenchymal stem cells successfully deliver oncolytic virotherapy to diffuse intrinsic pontine glioma","volume":"27","author":"Chastkofsky","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"6230","key":"10.1016\/j.ajps.2022.100771_bib0102","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1126\/science.aaa6204","article-title":"T cell exclusion, immune privilege, and the tumor microenvironment","volume":"348","author":"Joyce","year":"2015","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.ajps.2022.100771_bib0103","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/14653240600855905","article-title":"Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement","volume":"8","author":"Dominici","year":"2006","journal-title":"Cytotherapy"},{"issue":"5411","key":"10.1016\/j.ajps.2022.100771_bib0104","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1126\/science.284.5411.143","article-title":"Multilineage potential of adult human mesenchymal stem cells","volume":"284","author":"Pittenger","year":"1999","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.ajps.2022.100771_bib0105","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.3346\/jkms.2015.30.10.1405","article-title":"Therapeutic effects of mesenchymal stem cells for patients with chronic liver diseases: systematic review and meta-analysis","volume":"30","author":"Kim","year":"2015","journal-title":"J Korean Med Sci"},{"issue":"17","key":"10.1016\/j.ajps.2022.100771_bib0106","doi-asserted-by":"crossref","first-page":"4503","DOI":"10.1158\/0008-5472.CAN-18-3900","article-title":"Mesenchymal stem cell-mediated delivery of an oncolytic adenovirus enhances antitumor efficacy in hepatocellular carcinoma","volume":"79","author":"Yoon","year":"2019","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.ajps.2022.100771_bib0107","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.jhep.2013.07.010","article-title":"Systemically delivered measles virus-infected mesenchymal stem cells can evade host immunity to inhibit liver cancer growth","volume":"59","author":"Ong","year":"2013","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.ajps.2022.100771_bib0108","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1089\/hum.1997.8.1-37","article-title":"Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration","volume":"8","author":"Worgall","year":"1997","journal-title":"Hum Gene Ther"},{"issue":"6","key":"10.1016\/j.ajps.2022.100771_bib0109","doi-asserted-by":"crossref","first-page":"11692","DOI":"10.3390\/ijms140611692","article-title":"Wharton's jelly-derived mesenchymal stem cells: phenotypic characterization and optimizing their therapeutic potential for clinical applications","volume":"14","author":"Kim","year":"2013","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.ajps.2022.100771_bib0110","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jaut.2007.12.008","article-title":"Cell and gene therapy using mesenchymal stem cells (MSCs)","volume":"30","author":"Ozawa","year":"2008","journal-title":"J Autoimmun"},{"issue":"21","key":"10.1016\/j.ajps.2022.100771_bib0111","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1093\/jnci\/djh299","article-title":"Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents","volume":"96","author":"Studeny","year":"2004","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"10.1016\/j.ajps.2022.100771_bib0112","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1002\/stem.533","article-title":"Targeting of XIAP combined with systemic mesenchymal stem cell-mediated delivery of sTRAIL ligand inhibits metastatic growth of pancreatic carcinoma cells","volume":"28","author":"Mohr","year":"2010","journal-title":"Stem Cells"},{"issue":"32","key":"10.1016\/j.ajps.2022.100771_bib0113","doi-asserted-by":"crossref","first-page":"51815","DOI":"10.18632\/oncotarget.10122","article-title":"E1A-engineered human umbilical cord mesenchymal stem cells as carriers and amplifiers for adenovirus suppress hepatocarcinoma in mice","volume":"7","author":"Li","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ajps.2022.100771_bib0114","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.coi.2015.01.011","article-title":"Targeting the tumor vasculature to enhance T cell activity","volume":"33","author":"Lanitis","year":"2015","journal-title":"Curr Opin Immunol"},{"issue":"12","key":"10.1016\/j.ajps.2022.100771_bib0115","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1089\/hum.2012.043","article-title":"Evaluation of monocytes as carriers for armed oncolytic adenoviruses in murine and Syrian hamster models of cancer","volume":"23","author":"Bunuales","year":"2012","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.ajps.2022.100771_bib0116","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.omtm.2020.06.010","article-title":"Transient chimeric Ad5\/37 fiber enhances NK-92 carrier cell-mediated delivery of oncolytic adenovirus type 5 to tumor cells","volume":"18","author":"Gao","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.ajps.2022.100771_bib0117","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.omtm.2018.03.008","article-title":"Enhanced production of exosome-associated AAV by overexpression of the tetraspanin CD9","volume":"9","author":"Schiller","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"23","key":"10.1016\/j.ajps.2022.100771_bib0118","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1182\/bloodadvances.2017010181","article-title":"Enhanced liver gene transfer and evasion of preexisting humoral immunity with exosome-enveloped AAV vectors","volume":"1","author":"Meliani","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.ajps.2022.100771_bib0119","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2020.574007","article-title":"Extracellular vesicles-mimetic encapsulation improves oncolytic viro-immunotherapy in tumors with low coxsackie and adenovirus receptor","volume":"8","author":"Zhang","year":"2020","journal-title":"Front Bioeng Biotechnol"},{"issue":"7","key":"10.1016\/j.ajps.2022.100771_bib0120","doi-asserted-by":"crossref","first-page":"810","DOI":"10.2174\/156800911796798896","article-title":"Current targeting strategies for adenovirus vectors in cancer gene therapy","volume":"11","author":"Yao","year":"2011","journal-title":"Curr Cancer Drug Targets"},{"issue":"2","key":"10.1016\/j.ajps.2022.100771_bib0121","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jconrel.2012.02.013","article-title":"Polymer coatings for delivery of nucleic acid therapeutics","volume":"161","author":"Laga","year":"2012","journal-title":"J Control Release"},{"issue":"2","key":"10.1016\/j.ajps.2022.100771_bib0122","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1021\/mp300366f","article-title":"Adenoviral vectors coated with PAMAM dendrimer conjugates allow CAR independent virus uptake and targeting to the EGF receptor","volume":"10","author":"Vetter","year":"2013","journal-title":"Mol Pharm"},{"issue":"8","key":"10.1016\/j.ajps.2022.100771_bib0123","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.2967\/jnumed.112.115493","article-title":"Systemic image-guided liver cancer radiovirotherapy using dendrimer-coated adenovirus encoding the sodium iodide symporter as theranostic gene","volume":"54","author":"Grunwald","year":"2013","journal-title":"J Nucl Med"},{"issue":"7","key":"10.1016\/j.ajps.2022.100771_bib0124","doi-asserted-by":"crossref","first-page":"949","DOI":"10.3390\/pharmaceutics13070949","article-title":"Polymer coated oncolytic adenovirus to selectively target hepatocellular carcinoma cells","volume":"13","author":"Garofalo","year":"2021","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.ajps.2022.100771_bib0125","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1021\/mp400703d","article-title":"Evading immune cell uptake and clearance requires PEG grafting at densities substantially exceeding the minimum for brush conformation","volume":"11","author":"Yang","year":"2014","journal-title":"Mol Pharm"},{"key":"10.1016\/j.ajps.2022.100771_bib0126","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jconrel.2015.05.265","article-title":"Increasing the density of nanomedicines improves their ultrasound-mediated delivery to tumours","volume":"210","author":"Mo","year":"2015","journal-title":"J Control Release"},{"issue":"11","key":"10.1016\/j.ajps.2022.100771_bib0127","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/s41419-020-03223-0","article-title":"The armed oncolytic adenovirus ZD55-IL-24 eradicates melanoma by turning the tumor cells from the self-state into the nonself-state besides direct killing","volume":"11","author":"Hu","year":"2020","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.ajps.2022.100771_bib0128","doi-asserted-by":"crossref","first-page":"421","DOI":"10.3389\/fonc.2020.00421","article-title":"Combination therapy of prostate cancer by oncolytic adenovirus harboring interleukin 24 and ionizing radiation","volume":"10","author":"Mao","year":"2020","journal-title":"Front Oncol"},{"issue":"12","key":"10.1016\/j.ajps.2022.100771_bib0129","doi-asserted-by":"crossref","first-page":"11548","DOI":"10.1021\/acsnano.6b06182","article-title":"Oncolytic adenovirus complexes coated with lipids and calcium phosphate for cancer gene therapy","volume":"10","author":"Chen","year":"2016","journal-title":"ACS Nano"},{"issue":"6","key":"10.1016\/j.ajps.2022.100771_bib0130","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/nrd4643","article-title":"Oncolytic viruses get a boost with first FDA-approval recommendation","volume":"14","author":"Dolgin","year":"2015","journal-title":"Nat Rev Drug Discov"},{"issue":"19","key":"10.1016\/j.ajps.2022.100771_bib0131","doi-asserted-by":"crossref","first-page":"5317","DOI":"10.1039\/D0BM00681E","article-title":"Biosilicified oncolytic adenovirus for cancer viral gene therapy","volume":"8","author":"Kong","year":"2020","journal-title":"Biomater Sci"},{"key":"10.1016\/j.ajps.2022.100771_bib0132","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.3389\/fimmu.2019.02303","article-title":"In situ vaccination by direct dendritic cell inoculation: the coming of age of an old idea?","volume":"10","author":"Castiello","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.ajps.2022.100771_bib0133","doi-asserted-by":"crossref","first-page":"604","DOI":"10.3389\/fimmu.2019.00604","article-title":"Targeted APC activation in cancer immunotherapy to enhance the abscopal effect","volume":"10","author":"Suek","year":"2019","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.ajps.2022.100771_bib0134","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1021\/acsnano.8b08346","article-title":"In situ dendritic cell vaccine for effective cancer immunotherapy","volume":"13","author":"Yang","year":"2019","journal-title":"ACS Nano"},{"issue":"7","key":"10.1016\/j.ajps.2022.100771_bib0135","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1591875","article-title":"Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma","volume":"8","author":"Bommareddy","year":"2019","journal-title":"Oncoimmunology"},{"issue":"4","key":"10.1016\/j.ajps.2022.100771_bib0136","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.ccell.2018.03.005","article-title":"Emerging concepts for immune checkpoint blockade-based combination therapies","volume":"33","author":"Zappasodi","year":"2018","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.ajps.2022.100771_bib0137","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2017.06.017","article-title":"Antibodies against immune checkpoint molecules restore functions of tumor-infiltrating T cells in hepatocellular carcinomas","volume":"153","author":"Zhou","year":"2017","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.ajps.2022.100771_bib0138","doi-asserted-by":"crossref","first-page":"532","DOI":"10.3390\/vaccines9050532","article-title":"The evolving role of immune checkpoint inhibitors in hepatocellular carcinoma treatment","volume":"9","author":"Leone","year":"2021","journal-title":"Vaccines"},{"issue":"5","key":"10.1016\/j.ajps.2022.100771_bib0139","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1158\/2326-6066.CIR-19-0628","article-title":"Intratumoral delivery of a PD-1-blocking scFv encoded in oncolytic HSV-1 promotes antitumor immunity and synergizes with TIGIT blockade","volume":"8","author":"Lin","year":"2020","journal-title":"Cancer Immunol Res"},{"issue":"3","key":"10.1016\/j.ajps.2022.100771_bib0140","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1593\/tlo.12115","article-title":"Hypoxia moderates \u03b3(1)34.5-deleted herpes simplex virus oncolytic activity in human glioma xenoline primary cultures","volume":"5","author":"Friedman","year":"2012","journal-title":"Transl Oncol"},{"issue":"8","key":"10.1016\/j.ajps.2022.100771_bib0141","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1099\/vir.0.000138","article-title":"An investigation of herpes simplex virus type 1 latency in a novel mouse dorsal root ganglion model suggests a role for ICP34.5 in reactivation","volume":"96","author":"Mattila","year":"2015","journal-title":"J Gen Virol"},{"issue":"2","key":"10.1016\/j.ajps.2022.100771_bib0142","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.cyto.2015.05.030","article-title":"GM-CSF: an immune modulatory cytokine that can suppress autoimmunity","volume":"75","author":"Bhattacharya","year":"2015","journal-title":"Cytokine"},{"issue":"8","key":"10.1016\/j.ajps.2022.100771_bib0143","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1615817","article-title":"Vaccinia-based oncolytic immunotherapy pexastimogene devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter phase IIb trial (TRAVERSE)","volume":"8","author":"Moehler","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ajps.2022.100771_bib0144","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.canlet.2021.01.014","article-title":"Tumor-tagging by oncolytic viruses: a novel strategy for CAR-T therapy against solid tumors","volume":"503","author":"Tang","year":"2021","journal-title":"Cancer Lett"},{"issue":"2","key":"10.1016\/j.ajps.2022.100771_bib0145","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.ymthe.2020.10.023","article-title":"Clinical CAR-T cell and oncolytic virotherapy for cancer treatment","volume":"29","author":"Watanabe","year":"2021","journal-title":"Mol Ther"},{"issue":"4","key":"10.1016\/j.ajps.2022.100771_bib0146","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/ajg.2011.425","article-title":"Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors","volume":"107","author":"Shiina","year":"2012","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.ajps.2022.100771_bib0147","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1136\/gutjnl-2014-308286","article-title":"Additive antitumour response to the rabbit VX2 hepatoma by combined radio frequency ablation and toll like receptor 9 stimulation","volume":"65","author":"Behm","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.ajps.2022.100771_bib0148","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.omto.2020.08.010","article-title":"Neoadjuvant use of oncolytic herpes virus G47\u2206 enhances the antitumor efficacy of radiofrequency ablation","volume":"18","author":"Yamada","year":"2020","journal-title":"Mol Ther Oncolytics"},{"issue":"11","key":"10.1016\/j.ajps.2022.100771_bib0149","doi-asserted-by":"crossref","first-page":"10533","DOI":"10.1021\/acsnano.6b06530","article-title":"Mild hyperthermia induced by gold nanorod-mediated plasmonic photothermal therapy enhances transduction and replication of oncolytic adenoviral gene delivery","volume":"10","author":"Jung","year":"2016","journal-title":"ACS Nano"},{"issue":"1","key":"10.1016\/j.ajps.2022.100771_bib0150","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1080\/02656736.2019.1569731","article-title":"Orthotopic hepatocellular carcinoma: molecular imaging-monitored intratumoral hyperthermia-enhanced direct oncolytic virotherapy","volume":"36","author":"Song","year":"2019","journal-title":"Int J Hyperthermia"},{"issue":"2","key":"10.1016\/j.ajps.2022.100771_bib0151","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1080\/02656736.2016.1229045","article-title":"Radiofrequency hyperthermia-enhanced herpes simplex virus-thymidine kinase\/ganciclovir direct intratumoral gene therapy of hepatocellular carcinoma","volume":"33","author":"Wang","year":"2017","journal-title":"Int J Hyperthermia"},{"issue":"5 Suppl 1","key":"10.1016\/j.ajps.2022.100771_bib0152","doi-asserted-by":"crossref","first-page":"S179","DOI":"10.1053\/j.gastro.2004.09.032","article-title":"Chemoembolization for hepatocellular carcinoma","volume":"127","author":"Bruix","year":"2004","journal-title":"Gastroenterology"},{"issue":"16","key":"10.1016\/j.ajps.2022.100771_bib0153","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.3748\/wjg.v17.i16.2143","article-title":"P53 gene therapy in combination with transcatheter arterial chemoembolization for HCC: one-year follow-up","volume":"17","author":"Guan","year":"2011","journal-title":"World J Gastroenterol"},{"issue":"6","key":"10.1016\/j.ajps.2022.100771_bib0154","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s11605-018-3703-3","article-title":"Increased overall survival and decreased cancer-specific mortality in patients with hepatocellular carcinoma treated by transarterial chemoembolization and human adenovirus type-5 combination therapy: a competing risk analysis","volume":"22","author":"He","year":"2018","journal-title":"J Gastrointest Surg"},{"issue":"3","key":"10.1016\/j.ajps.2022.100771_bib0155","first-page":"1649","article-title":"Adenovirus-mediated herpes simplex virus thymidine kinase gene therapy combined with ganciclovir induces hepatoma cell apoptosis","volume":"17","author":"Zhang","year":"2019","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.ajps.2022.100771_bib0156","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.omto.2019.10.007","article-title":"Oncolytic viruses for cancer therapy: barriers and recent advances","volume":"15","author":"Zheng","year":"2019","journal-title":"Mol Ther Oncolytics"}],"container-title":["Asian Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1818087622001209?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1818087622001209?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T07:49:04Z","timestamp":1761724144000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1818087622001209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":156,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S1818087622001209"],"URL":"https:\/\/doi.org\/10.1016\/j.ajps.2022.100771","relation":{},"ISSN":["1818-0876"],"issn-type":[{"value":"1818-0876","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oncolytic virus-based hepatocellular carcinoma treatment: Current status, intravenous delivery strategies, and emerging combination therapeutic solutions","name":"articletitle","label":"Article Title"},{"value":"Asian Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajps.2022.100771","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Shenyang Pharmaceutical University. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100771"}}